Proloc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proloc

Proloc: A Definition and Pharmacological Classification

Property Description
Active ingredient Omeprazole
Form Oral (Capsules, Tablets)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Gastric Acid Secretion Inhibition
Origin Synthetic (Substituted Benzimidazole)

Proloc is a medication whose active ingredient is Omeprazole, a synthetic substance classified as a Proton Pump Inhibitor (PPI). It is primarily identified as a Gastric Acid Secretion Inhibitor due to its specific and potent action on the mechanisms responsible for acid production in the stomach lining. Omeprazole is a single-ingredient product belonging chemically to the substituted benzimidazole class. This classification is vital, as the medication provides a consistent ability to achieve profound and sustained acid control. The drug's therapeutic capability involves its efficacy in providing extended relief compared to acid-reducing agents with a different mechanism of action.


Composition, Origin, and Available Forms

Proloc is most commonly prepared in oral dosage forms, typically as capsules or tablets, which are designed for delayed-release. This delayed-release formulation is critical because the active ingredient, Omeprazole, is sensitive to stomach acid; the special enteric coating ensures the medication remains intact as it passes through the stomach. The drug is intended for oral administration and is only dissolved and absorbed when it reaches the less acidic environment of the small intestine. This specific delayed-release formulation is essential to bypass gastric degradation and maximize the drug's therapeutic effect. This specialized coating ensures a reliable quantity of the Omeprazole is delivered intact, a crucial feature for the drug's effectiveness.


General Purpose and How it Helps the Digestive System

The general purpose of Proloc is to significantly and reliably reduce the production of acid within the stomach cavity. By achieving this profound suppression, the medication helps to create a low-acid environment that alleviates the burning discomfort caused by the backflow of stomach contents. This action is crucial, as the resulting sustained control over acidity allows the body's natural processes to heal irritated or damaged tissues in the upper digestive tract. It is typically used to provide relief in scenarios where acid irritation is constant, such as persistent heartburn or overnight acid symptoms.

Regulatory References

  1. NIH: Omeprazole, Delayed-Release

What side effects are possible with Proloc?

Official Safety Profile and Adverse Reactions

The possible side effects and safety characteristics of Proloc (Omeprazole) are documented in official regulatory sources, classifying reactions by frequency and affected organ system. This information is intended to communicate the medicine's risk profile based on clinical data.

Frequency-Classified Adverse Reactions

The incidence of documented adverse events is formally classified by regulatory standards:

  • Common: These are the most frequently reported reactions and include headache, abdominal pain, diarrhea, constipation, flatulence, and nausea/vomiting.
  • Uncommon: Reactions such as insomnia, dizziness, paraesthesia, increased liver enzymes, rash, pruritus, urticaria, malaise, and peripheral oedema are officially categorized here.
  • Rare: Less frequent events documented include hypersensitivity reactions (e.g., fever, angioedema, anaphylactic shock), blood disorders like leukopenia and thrombocytopenia, hyponatraemia, and severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Systemic Safety Considerations

Adverse events are grouped by the official System-Organ Classes (SOC) found in the prescribing information, including Gastrointestinal disorders, Nervous system disorders, Skin and subcutaneous tissue disorders, and Blood and lymphatic system disorders. Official safety statements highlight risks related to exposure duration:

  • Long-Term Exposure: Hypomagnesaemia, Vitamin B12 deficiency, and an increased risk of bone fractures (hip, wrist, or spine) are associated with prolonged or long-term use, typically defined as months or years of therapy.
  • Specific Patient Groups: Caution is noted for patients with pre-existing hepatic impairment due to potential changes in systemic exposure. Additionally, official regulatory texts indicate that Proloc is contraindicated in patients with a known hypersensitivity to omeprazole or other substituted benzimidazoles, or when co-administered with nelfinavir. The development of acute tubulointerstitial nephritis (ATIN) is also documented as a serious reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Proloc (Omeprazole) overdose details a set of expected, primarily transient clinical manifestations. If overdosage is suspected, emergency medical attention must be sought immediately. This instruction is consistent across major regulatory bodies, emphasizing the need to call the Poison Help line or contact emergency services regardless of whether symptoms are currently present.

Documented Manifestations and Severity

Overdose exposures documented in clinical settings have reported a range of symptoms affecting the central nervous system, cardiovascular system, and gastrointestinal tract. These officially documented presentations include confusion, somnolence (drowsiness), headache, tachycardia (increased heart rate), blurred vision, nausea, vomiting, dryness of the mouth, flushing, and increased sweating (diaphoresis).

Regulatory information notes that despite ingestion of high single doses (up to 900 mg), the reported symptoms have been transient, and no serious clinical outcome has been officially reported.

Supportive Management and Antidote Status

The official management of Proloc overdosage is strictly symptomatic and supportive. This approach is required because no specific antidote is known for Omeprazole. Furthermore, regulatory documents specify that the active ingredient is extensively protein-bound, meaning that it is not readily dialyzable, rendering procedures like hemodialysis ineffective in removing the drug. No specific population-based differences in overdose management are detailed in official labeling.

Therapeutic Uses of Proloc

What Proloc Treats: Main Uses and Benefits

The medication is commonly used in therapeutic domains involving excessive gastric acid and acid-related tissue damage. It is generally applied in contexts involving inflammatory or irritative states and symptoms related to physical discomfort.


Key Therapeutic Applications and Benefits

Proloc is commonly used to help with the recurrent manifestations of Gastroesophageal Reflux Disease (GERD), which includes frequent heartburn and acid regurgitation. It assists with maintaining functional stability by managing these symptoms that interfere with daily functioning. The primary indications also play a role in managing active peptic ulcers (both gastric and duodenal) and erosive esophagitis. Additionally, it may contribute to supporting the reduction of ulceration risk in patients taking certain medications, like NSAIDs.

“This medication supports the patient during difficult episodes by easing distress and managing the recurrence of highly disruptive symptoms.”

It is considered relevant for managing specialized, chronic conditions, such as Zollinger-Ellison Syndrome, which are characterized by periods of heightened symptoms due to pathologically excessive acid output. Proloc provides supportive relief and may assist with managing these severe manifestations. It supports a more manageable experience of day-to-day comfort in situations requiring prolonged management.


Quick Fact Summary

  • Indications Include: GERD, duodenal ulcers, gastric ulcers, erosive esophagitis, and pathological hypersecretory conditions.
  • Quick Fact: Relief for Persistent Heartburn — Proloc supports a more manageable experience of day-to-day comfort in situations requiring prolonged management, contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Absolute Contraindications

Proloc is contraindicated and must not be used in patients with a known hypersensitivity to the active ingredient, Omeprazole, any component of the formulation, or to other substituted benzimidazoles. Use is also strictly prohibited in patients who are concurrently receiving rilpivirine-containing products, as stated in the official prescribing information.


Age-Based and Condition-Based Eligibility

Category Regulatory Status
Pediatric Use (1 month to 16 years) Approved for treatment of Erosive Esophagitis (EE) starting at 1 month of age; approved for symptomatic GERD and maintenance of healed EE starting at 1 year of age.
Infants (<1 month) Safety and effectiveness have not been established.
Adults and Older Adults Approved for all labeled indications. No dose adjustment is typically required for geriatric patients.
Hepatic Impairment Use requires caution; regulatory guidance suggests a reduced daily dose may be sufficient in severe impairment.
Gastric Malignancy The presence of malignancy must be excluded in adults before treatment begins.

Pregnancy and Lactation

Official data on use during pregnancy suggests the medicine is generally accepted, with extensive data indicating no evidence of malformative or feto/neonatal toxicity. Omeprazole is excreted in human milk; limited data suggests maternal doses would not cause adverse effects in breastfed infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Proloc (Omeprazole) is defined by its two primary actions: inhibiting the CYP2C19 metabolic pathway and significantly altering gastric pH. Regulatory documents establish strict constraints for co-administration based on these effects.

Interaction Restrictions

Co-administration is contraindicated with specific antiretroviral agents, including Nelfinavir and Rilpivirine-containing products, due to the risk of severely reduced plasma concentrations of the co-administered drug. The label also specifies that co-administration with Atazanavir is not recommended.

Documented Pharmacokinetic Effects

Interacting Substance/Class Official Interaction Outcome
CYP2C19 Inhibitor Action (e.g., Diazepam, Phenytoin) Prolonged elimination and increased systemic exposure of the co-administered drug.
pH-Dependent Absorption Drugs (e.g., Ketoconazole, Iron salts) Decreased absorption of the co-administered drug.
pH-Dependent Absorption Drug (e.g., Digoxin) Increased plasma levels of the co-administered drug.
CYP Inducers (e.g., St. John’s Wort, Rifampin) Reduced plasma concentrations of Omeprazole; co-administration should be avoided.

Furthermore, the antiplatelet effect of Clopidogrel is officially noted to be reduced by Omeprazole through CYP2C19 inhibition. A procedural constraint requires that Proloc must be stopped at least 14 days prior to certain diagnostic tests, such as assessing Chromogranin A ( CgA) levels, to avoid interference.

Mechanism of Action

Targeting the Primary Receptor System

Proloc exerts its action by engaging a specific receptor system where it functions as a targeted antagonist. This molecular interaction involves Proloc binding to the receptor site, which physically obstructs the binding of the body's natural signaling molecules. This action prevents the receptor's activation, thereby interrupting the signal chain at its origin.

Modulating Signal Transduction Pathways

The receptor blockade achieved by Proloc subsequently modulates the resulting signal transduction cascade within the cell. The drug's mechanistic domain operates within systems characterized by overactive or heightened signaling and decreases the magnitude of the cellular response that typically follows the receptor's activation.

Influencing Core Regulatory Systems

This molecular effect translates to influencing core regulatory systems by altering activity within the affected pathway. This mechanism ultimately decreases excessive signaling within central or peripheral pathways, which is the basis of the drug's mechanistic profile.

Dosage and Administration Information

How to Use Proloc (Pantoprazole 20 mg)

Proloc tablets contain the active substance pantoprazole in a gastro-resistant formulation. Adherence to specific administration instructions is essential for the correct use and delivery of the medicine.

Administration and Dosage Rules

Usage Domain Instruction
Route & Preparation Swallow the tablet whole with liquid; do not chew or crush the gastro-resistant tablet.
Dosing Schedule The recommended dose is one 20 mg tablet once per day.
Timing The tablet should be taken before a meal or with or without food.
Missed Dose If a dose is missed, do not take a double dose. Take the next, normal dose at the usual time.

Treatment Duration and Consultation

This medicine is intended for short-term use in adults. Treatment duration is defined by the following parameters:

  • Initial Review: If no symptom relief is obtained after two weeks of continuous treatment, a doctor must be consulted.
  • Maximum Duration: Treatment should not exceed four weeks without seeking medical advice.
  • Stopping Use: Treatment should be discontinued once complete relief of symptoms has occurred.

Age-Specific Use

Proloc (pantoprazole 20 mg) is not recommended for use in children and adolescents below 18 years of age due to insufficient data on its safety and efficacy for this age group.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Proloc (Omeprazole)

The information presented here describes the research that has been conducted on the active ingredient in Proloc, Omeprazole. This section is intended to provide context on the types of studies that exist, the outcomes they measured, and where scientific uncertainty may remain. It is not intended as medical advice or a statement of individual response.

Evidence for Use in Symptomatic Heartburn and GERD

Research has examined symptoms associated with Gastroesophageal Reflux Disease (GERD), including frequent heartburn, and includes Randomized Controlled Trials (RCTs). These studies were used in research exploring whether symptom patterns changed over time when compared to a placebo or other therapies. Researchers focused on outcomes related to physical discomfort, such as the reported resolution or intensity of heartburn and acid regurgitation over a few weeks.

Findings describe patterns of symptom measurement in the observed groups over the short periods of the trials. Some trials described patterns of symptom stability when the medication was observed in longer studies. However, the existing research provides limited information for long-term outcomes beyond the initial study periods, and data for certain groups remain insufficient.

Research on Healing Erosive Esophagitis

Dedicated clinical trials were conducted to evaluate the healing of tissue damage in the esophagus, known as erosive esophagitis (EE). These studies primarily focused on objective measures, such as the endoscopic healing rate—that is, the physical closure of lesions as seen by a doctor. Studies monitored patient status related to recurrence in observed patients who continued to be observed over defined time intervals after initial healing.

Research highlights that trials reported measured levels of mucosal healing in the observed populations following the acute treatment phase. Findings from maintenance studies describe patterns where the medication was studied for monitoring recurrence of the erosive lesions. Follow-up durations were limited, which means that long-term outcomes are not well characterized regarding the absolute recurrence patterns over many years.

Studies for Peptic Ulcer Healing and Prevention

The research examining peptic ulcers, including both gastric and duodenal ulcers, was primarily conducted through short-term RCTs. Studies explored two main outcomes: the endoscopic assessment of ulcer healing rates and the time required for healing. The research also included studies where the active ingredient was evaluated as part of combination regimens for managing Helicobacter pylori.

Studies reported measurements related to ulcer healing rates over short-term periods. Trials also described patterns observed in studies monitoring the recurrence of ulcers, particularly when used in patients who were also taking certain types of pain medications (NSAIDs). The evidence contributes to understanding the healing patterns within the observed populations. However, follow-up durations were limited in many healing trials, and the research has not consistently characterized a typical duration for maintenance therapy across all patient groups.

Frequently Asked Questions (FAQ)

Common questions about Proloc (FAQ)

Q: Does Proloc contain any common allergens like gluten or lactose?

Official regulatory labeling includes a full list of inactive ingredients, also known as excipients, in the formulation of Proloc. This list details all components, which typically includes information regarding common allergens such as gluten or lactose, if they are present. This information is documented to provide clarity on the product's exact composition.

Q: How quickly does Proloc start to work after starting treatment?

According to official product information for the active ingredient, Proloc is not designed to provide immediate relief for acid symptoms. Studies and official warnings state that it may take 1 to 4 days of continued use before the full, sustained effect of the medicine is typically noticeable.

Q: Do I need to change my diet while taking Proloc?

Official patient information often suggests that individuals may benefit from certain lifestyle changes to help manage their symptoms. Recommendations typically suggest avoiding foods that are associated with increasing stomach acid or irritation, such as rich, spicy, or fatty foods, as well as minimizing alcohol or caffeine intake.

Q: What happens if I stop taking Proloc suddenly?

Stopping the medication abruptly, particularly after long-term use, is associated with a phenomenon where the body temporarily increases acid production (known as rebound acid hypersecretion), which may cause the recurrence of the original reflux symptoms.

Q: Does Proloc interact with common pain relievers like ibuprofen or aspirin?

While regulatory documents generally do not indicate a significant drug-drug interaction for non-antiplatelet pain relievers like ibuprofen, the official caution highlights that the label notes a potential for a slightly higher occurrence of digestive tract adverse events when the medication is used concurrently with certain nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: Is it okay to drink alcohol in moderation while on Proloc?

Regulatory documents indicate there is no direct drug-drug interaction between Proloc and alcohol. However, official guidance indicates that consuming alcohol is a factor that may increase the production of stomach acid, which could potentially worsen the underlying acid-related symptoms.

Q: Is Proloc available over the counter, or is it prescription only?

Proloc is available in both prescription (Rx) and over-the-counter (OTC) formulations. The availability depends on the dosage and the specific condition it is being used to treat, as defined in the regulatory labeling.

Q: How does Proloc interact with birth control pills?

Official drug interaction studies and product information state that Proloc does not generally reduce the effectiveness of combined oral contraceptives (birth control pills). No clinically significant interaction that would compromise the action of these medications is documented.

Q: Is there a generic version of Proloc available?

Regulatory databases confirm the availability of generic formulations. These products are approved under strict regulatory standards to ensure they are comparable to the brand-name medication in terms of quality and performance.

Q: Is Proloc known to cause weight gain or weight loss?

Weight changes are not categorized as common or uncommon adverse reactions in clinical trial data. However, both weight gain and weight loss have been documented in post-marketing surveillance reports, which collect information on side effects after the product is widely available.

Q: Are there any foods or drinks I should absolutely avoid while taking Proloc?

Official patient guidance discusses avoiding certain foods and drinks that are known to irritate the stomach lining, such as fatty or spicy foods, as well as common irritants like caffeine, as minimizing these may help reduce acid-related symptoms.

Q: Can Proloc cause problems with vision?

Official regulatory documents list visual disturbances as an event that has been documented in some patients. This issue is categorized among the rare or very rare adverse reactions in the overall safety profile.

Q: How long does Proloc stay in your system after you stop taking it?

The official pharmacokinetic data indicates that the plasma elimination half-life of the active ingredient is typically very short, often less than one hour. This means the substance is rapidly processed and eliminated by the body.

Q: Does Proloc have an interaction with grapefruit or grapefruit juice?

Although not classified as a major clinical interaction, official documents note that grapefruit juice can potentially affect the metabolism of the active ingredient. This is due to its known effect on the CYP3A4 enzyme pathway, which is involved in processing the drug.

Q: Is Proloc safe for individuals with a history of mental health issues?

Regulatory labeling lists certain psychiatric disorders as rare or very rare side effects documented in clinical experience. These include reports of confusion, agitation, and depression in some patients taking the medication.

Q: Does Proloc interact with common cold or flu medications?

The official interaction profile may specify that the medication does not interact with common cold components, such as acetaminophen. However, patients are often advised to use caution regarding cold or flu products that contain multiple active ingredients.

Q: What should I do if I accidentally take more Proloc than recommended?

The official labeling for the product requires a clear warning about the risk of overdose. In the event that more medication is accidentally taken than is recommended, the instruction is to seek medical help or contact a Poison Control Center immediately.

How should Proloc be stored and disposed of?

How to Store and Dispose of Proloc (Omeprazole)

Official regulatory guidelines dictate specific storage and disposal requirements for Proloc to protect its moisture-sensitive formulation.


Storage Requirements

Requirement Details (Official Labeling)
Temperature Store at room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and protect it from moisture and excess heat.
Prohibited Do not refrigerate or store in high-humidity areas like the bathroom.
Child Safety Keep the medication out of the reach and sight of children.

Disposal Instructions

Unused or expired Proloc should be managed through an official drug take-back program when available. If a take-back program is not accessible, the product may be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed bag, and discarded in the household trash. The medication must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proloc found in:

A-Z Index: